Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
NCT03260192 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2024-01-10
Summary
Investigators aim to investigate whether circulating tumor DNA is a sensitive marker to evaluate patients' response to neoadjuvant chemotherapy
Conditions
Sponsors & Collaborators
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
lead OTHER
Principal Investigators
-
qiang Liu · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-09-01
- Primary Completion
- 2025-12-01
- Completion
- 2025-12-01
Countries
- China
More Related Trials
-
ctDNA Monitoring in Early Breast Cancer
NCT04353557 ·Status: RECRUITING
-
Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia
NCT05050890 ·Status: UNKNOWN
-
Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients
NCT06479460 ·Status: RECRUITING
-
Clinical Application of CTDNA in Operable Breast Cancer Patients
NCT02797652 ·Status: UNKNOWN
-
Study on Early Auxiliary Diagnosis and Postoperative Recurrence Monitoring of Breast Cancer
NCT05858242 ·Status: RECRUITING
-
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer
NCT05079074 ·Status: COMPLETED
-
Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
NCT03709134 ·Status: COMPLETED
-
Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer
NCT04308720 ·Status: ACTIVE_NOT_RECRUITING
-
Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy
NCT03381092 ·Status: UNKNOWN
-
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
NCT05427617 ·Status: COMPLETED
-
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT05770531 ·Status: RECRUITING ·Phase: PHASE2
-
Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
NCT02743910 ·Status: ACTIVE_NOT_RECRUITING
-
A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
NCT03047889 ·Status: UNKNOWN
-
Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test
NCT04264468 ·Status: UNKNOWN
-
A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
NCT06591039 ·Status: RECRUITING
-
Diagnostic Biomarkers Exploration of Breast Cancer From Serum and Urine
NCT06102018 ·Status: RECRUITING
-
Study of Circulating and Tumor Biomarkers in Breast Cancer Patients
NCT01866202 ·Status: UNKNOWN
-
Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis
NCT05730010 ·Status: COMPLETED
-
Clinical Application of ctDNA in Early Screening of Breast Cancer
NCT03973034 ·Status: UNKNOWN
-
Correlation Between Serum TK1 and Pathological Remission of Breast Cancer With Neoadjuvant Chemotherapy
NCT06509555 ·Status: RECRUITING
-
HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC
NCT05834699 ·Status: UNKNOWN
-
Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer Patients
NCT00952679 ·Status: UNKNOWN ·Phase: PHASE3
-
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928 ·Status: RECRUITING ·Phase: NA
-
Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer
NCT04021069 ·Status: UNKNOWN
-
The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer
NCT06698679 ·Status: RECRUITING